| Matthew C Gertsch, MD | |
|
1380 E Medical Center Dr, Saint George, UT 84790-2123 | |
| (435) 251-1000 | |
| Not Available |
| Full Name | Matthew C Gertsch |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 12 Years |
| Location | 1380 E Medical Center Dr, Saint George, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447518881 | NPI | - | NPPES |
| 100270146 | Medicaid | WI |
| Facility Name | Location | Facility Type |
|---|---|---|
| Dixie Regional Medical Center | St george, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mountain West Anesthesia Llc | 9032018502 | 248 |
News Archive
A compound tested by UT Southwestern Medical Center investigators destroys several viruses, including the deadly Spanish flu that killed an estimated 30 million people in the worldwide pandemic of 1918.
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that Palmetto GBA, a national contractor that administers Medicare benefits, has established coverage for the company's Corus CAD gene expression test for the evaluation of patients presenting with typical and atypical symptoms suggestive of coronary artery disease.
AtheroNova Inc., a biotech company focused on the research and development of compounds to regress atherosclerotic plaque has established a clear development plan, including Phase I and Phase II protocol outlines, based on the recently finalized minutes of its pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its AHRO-001, a compound for the treatment of atherosclerosis.
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
› Verified 9 days ago
| Entity Name | Mountain West Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558391763 PECOS PAC ID: 9032018502 Enrollment ID: O20040103000057 |
News Archive
A compound tested by UT Southwestern Medical Center investigators destroys several viruses, including the deadly Spanish flu that killed an estimated 30 million people in the worldwide pandemic of 1918.
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that Palmetto GBA, a national contractor that administers Medicare benefits, has established coverage for the company's Corus CAD gene expression test for the evaluation of patients presenting with typical and atypical symptoms suggestive of coronary artery disease.
AtheroNova Inc., a biotech company focused on the research and development of compounds to regress atherosclerotic plaque has established a clear development plan, including Phase I and Phase II protocol outlines, based on the recently finalized minutes of its pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its AHRO-001, a compound for the treatment of atherosclerosis.
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew C Gertsch, MD Po Box 3570, Salt Lake City, UT 84110-3570 Ph: (801) 727-2056 | Matthew C Gertsch, MD 1380 E Medical Center Dr, Saint George, UT 84790-2123 Ph: (435) 251-1000 |
News Archive
A compound tested by UT Southwestern Medical Center investigators destroys several viruses, including the deadly Spanish flu that killed an estimated 30 million people in the worldwide pandemic of 1918.
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that Palmetto GBA, a national contractor that administers Medicare benefits, has established coverage for the company's Corus CAD gene expression test for the evaluation of patients presenting with typical and atypical symptoms suggestive of coronary artery disease.
AtheroNova Inc., a biotech company focused on the research and development of compounds to regress atherosclerotic plaque has established a clear development plan, including Phase I and Phase II protocol outlines, based on the recently finalized minutes of its pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its AHRO-001, a compound for the treatment of atherosclerosis.
Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.
› Verified 9 days ago
Spencer G Wells, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 617 E Riverside Dr Ste 301, Saint George, UT 84790 Phone: 435-216-7000 Fax: 435-216-7001 | |
Seth Herway, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1380 E Medical Center Dr, Saint George, UT 84790 Phone: 435-251-1000 Fax: 770-701-6675 | |
Christopher Johnson, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1380 E Medical Center Dr, Saint George, UT 84790 Phone: 435-251-1000 | |
Dr. Ryan Kent Workman, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1490 E Foremaster Dr, Ste 220, Saint George, UT 84790 Phone: 435-216-7000 Fax: 435-216-7001 |